BPC-157 vs. TB-500
These two are marketed as a pair so relentlessly that comparing them feels like choosing between teammates. They are genuinely different molecules — a gastric-protein fragment versus a thymosin fragment — with genuinely similar evidence problems.
Both have animal-model literatures that are real and, in places, impressive. Neither has published controlled human trials. Neither is approved anywhere. Both appear in anti-doping prohibited frameworks. A comparison can rank their rodent data; it cannot tell you which 'works better' in humans, because that question has no tested answer for either.
The facts, side by side
| BPC-157 | TB-500 (Thymosin Beta-4) | |
|---|---|---|
| Regulatory status | Research-stage — not approved for human use | Research-stage — not approved for human use |
| Evidence level | Mostly animal/lab studies | Mostly animal/lab studies |
| Category | Recovery & Healing | Recovery & Healing |
Full profiles: BPC-157 · TB-500 (Thymosin Beta-4)
What they are
BPC-157 is a 15-amino-acid synthetic fragment related to a protective gastric protein, studied mostly in rodent injury models spanning tendon, ligament, gut and vasculature. TB-500 is a synthetic fragment of thymosin beta-4, a cell-migration protein, with its own animal wound-model literature.
Regulatory posture
BPC-157 drew explicit FDA attention — placed in Category 2 of the interim compounding list in 2023 on safety-concern grounds, with its status evolving since. TB-500 has mostly stayed beneath formal review, which is obscurity, not endorsement.
The evidence ceiling
Both stories top out at the same place: no published controlled human trials. Every human-benefit claim for either compound is an extrapolation from animals, whatever the dosage calculators and stack guides imply.
The bottom line
There is no evidence-based winner because neither compound has entered the arena where winning is defined — controlled human trials. If you're evaluating a clinic or product built on either, the vetting framework matters more than the molecule choice.
BPC-157 vs. TB-500 FAQ
More comparisons
Semaglutide vs. Tirzepatide
GLP-1 vs dual GIP/GLP-1 — how the two most prescribed weight-management peptides compare on evidence, average results, side effects and practical reality.
Tirzepatide vs. Retatrutide
One is an FDA-approved medicine; the other is an investigational triple agonist still in trials. The comparison that matters is regulatory status, not receptor count.
Semaglutide vs. Liraglutide
Two generations of the same drug class: how the weekly GLP-1 compares with its daily predecessor on results, track record and — increasingly — cost.
Build your own comparison